Overview In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
New York, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomedtracker / Meddevicetracker Q3 2020 Outlook Report" - https://www.reportlinker.com/p05955632/?utm_source=GNW
These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. The results of the drug catalysts highlighted in our Biomedtracker / Meddevicetracker Q2 2020 Outlook Report can be found on Page 6. At the end of this report, we have included a list of Large Impact catalysts through Q3 2020.
Acute Myelogenous Leukemia (AML)
Cardiac Valve Surgery
Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
Graft vs. Host Disease (GVHD) - Treatment
Major Depressive Disorder (MDD)
Mantle Cell Lymphoma - NHL
Multiple Myeloma (MM)
Multiple Sclerosis (MS)
Myelodysplastic Syndrome (MDS)
Osteoarthritis and Osteoarthritis Pain
Other Ophthalmological Indications (Ophthalmology)
Renal Disease / Renal Failure
Rheumatoid Arthritis (RA)
Seizure Disorders (Epilepsy)
Spinal Muscular Atrophy
Read the full report: https://www.reportlinker.com/p05955632/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001